About Wanbury Limited
Data last updated:
Wanbury Limited is a public limited company based in Navi Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 11 August 1988 and has been in existence for over 38 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L51900MH1988PLC048455. Its GSTIN is 27AABCP5939P1ZP (Maharashtra). The company holds 10 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 524212 and NSE: WANBURY.
The company has an authorised share capital of ₹50 Cr and a paid-up capital of ₹34.94 Cr. It was formerly known as Pearl Organics Ltd and Pearl Organics Pvt Ltd. It is led by directors including Chandran Krishnamoorthy (Whole-Time Director) and Mohan Kumar Rayana (Whole-Time Director).
Its last annual general meeting (AGM) was held on 18 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Sector 30, Navi Mumbai, Maharashtra.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹650.27 Cr, a growth of 8.5% compared to the previous year. For the same year it recorded a net profit of ₹69.66 Cr (net margin 10.7%) and EBITDA of ₹103.15 Cr (EBITDA margin 15.9%). The net worth stands at ₹144.45 Cr (up 143.7% YoY). Total assets are valued at ₹393.64 Cr (up 53.2% YoY).
The company has about 742 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Wanbury Limited. As per MCA filings, the company has open charges of ₹276 Cr and satisfied charges of ₹922.25 Cr on record. Court records list 154 cases involving the company, including 88 filed by the company and 67 filed against it; 19 cases are pending. The company has 57 deals on record (53 market trades, 1 debt financing, 1 secondary share transfer), with disclosed funding of ₹147.23 Cr; the latest was in July 2026. Its 7 peer companies in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 3 smaller; the largest is Samarth Life Sciences Private Limited with revenue of ₹624.79 Cr. The company has 12 MSME Form 1 returns on record between 2019 and 2024, listing 205 overdue payments to 27 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website wanbury.com.
Company details
Name history
Wanbury has undergone 3 name changes throughout its history. The company was previously known as Pearl Organics Ltd, Pearl Organics Pvt Ltd, and Pearl Distributors Pvt Ltd. The current legal name is Wanbury Limited.
| Company Name | Status |
|---|---|
| Wanbury Limited | Current |
| Pearl Organics Ltd | Previous |
| Pearl Organics Pvt Ltd | Previous |
| Pearl Distributors Pvt Ltd | Previous |
Contact details
Wanbury Limited's registered office is in Navi Mumbai, Maharashtra. Its website is wanbury.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressBsel Tech Park 'B; Wing 10th Floor Sector 30A Opp.Vashi Railway Station V, Ashi, Navi Mumbai, Maharashtra, India – 400703
- IndustryPharma, API Manufacturers
To see the full contact details of Wanbury Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Wanbury operates one associated brand: Wanbury Limited. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Anti-diabetic drugs and active pharmaceutical ingredients are manufactured. | wanbury.com |
Business activity
The main business activity of Wanbury is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Wanbury Limited, buy the company report.
Financials of Wanbury Limited
FY 2025-26 filings availableWanbury Limited reported revenue of ₹650.27 Cr (up 8.5% YoY) for FY 2025-26.
Financial Highlights
FY 2024-25 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 600 | 576 | 500 | 511 | 393 | 367 | 391 |
| Revenue growth | +4.1% | +15.2% | -2.3% | +30.2% | +6.8% | -6.1% | - |
| EBITDA | 76.31 | 70.00 | 22.58 | 35.32 | 18.02 | 23.43 | 15.55 |
| EBITDA margin | +12.7% | +12.2% | +4.5% | +6.9% | +4.6% | +6.4% | +4.0% |
| Profit before tax | 29.54 | 56.34 | (10.28) | 81.14 | (12.40) | 64.66 | (24.97) |
| Net profit | 33.36 | 33.23 | (6.79) | 5.76 | (12.24) | (18.05) | (24.49) |
| Net profit margin | +5.6% | +5.8% | -1.4% | +1.1% | -3.1% | -4.9% | -6.3% |
| EPS (₹) | 9.32 | 17.09 | (3.18) | 24.94 | (5.04) | 25.79 | 0.00 |
| Balance sheet | |||||||
| Total assets | 257 | 160 | 76.05 | 88.91 | 49.73 | 58.40 | 61.07 |
| Net worth | 59.27 | 27.95 | (32.81) | (23.42) | (156) | (143) | (209) |
| Total debt | 179 | 116 | 94.93 | 100 | 192 | 190 | 260 |
| Cash & bank | 12.83 | 5.90 | 3.93 | 25.31 | 11.70 | 16.70 | 5.25 |
| Net working capital | 36.42 | (24.27) | (106) | (92.40) | (142) | (130) | (131) |
| Cash flow | |||||||
| Cash from operations | 26.10 | 3.98 | 19.80 | 40.52 | 16.68 | 44.13 | 29.73 |
| Cash from investing | (51.17) | (16.63) | (8.84) | 0.59 | 8.04 | 63.66 | (3.07) |
| Cash from financing | 25.73 | 14.55 | (31.99) | (28.58) | (17.39) | (108) | (26.78) |
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 163 | 172 | 133 | 161 | 131 | 139 | 146 | 144 |
| Revenue growth (YoY) | +24.5% | +23.4% | -8.3% | +11.6% | -10.4% | - | - | - |
| Other income | 0.35 | 1.84 | 0.84 | 1.63 | 0.94 | 26.48 | 0.69 | 0.76 |
| EBITDA | 24.44 | 29.63 | 13.94 | 20.01 | 10.98 | 18.17 | 21.15 | 17.34 |
| EBITDA margin | +15.0% | +17.2% | +10.4% | +12.4% | +8.4% | +13.0% | +14.5% | +12.0% |
| Depreciation | 3.64 | 3.37 | 3.32 | 3.32 | 3.29 | 3.28 | 3.32 | 3.24 |
| Interest | 7.54 | 9.04 | 10.17 | 10.15 | 7.59 | 7.46 | 8.26 | 7.67 |
| Profit before tax | 13.61 | 19.06 | 1.29 | 8.17 | 1.04 | 33.91 | 10.26 | 7.19 |
| Tax | 0.12 | (1.20) | 0.07 | 0.15 | 0.00 | 0.27 | (0.02) | (0.18) |
| Net profit | 13.49 | 20.26 | 1.22 | 8.02 | 1.04 | 33.64 | 10.28 | 7.37 |
| EPS (₹) | 3.95 | 5.98 | 0.35 | 2.34 | 0.31 | 10.08 | 3.13 | 2.25 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 650 | 600 | 578 | 500 | 511 | 393 | 367 |
| Revenue growth | +8.5% | +3.8% | +15.6% | -2.3% | +30.2% | +6.8% | - |
| EBITDA | 103 | 76.41 | 72.10 | 22.58 | 35.33 | 18.02 | 23.43 |
| EBITDA margin | +15.9% | +12.8% | +12.5% | +4.5% | +6.9% | +4.6% | +6.4% |
| Profit before tax | 59.80 | 29.54 | 30.79 | (10.28) | 81.15 | (12.40) | 64.66 |
| Net profit | 69.66 | 28.47 | 29.92 | (10.08) | 5.44 | (13.81) | (18.17) |
| Net profit margin | +10.7% | +4.8% | +5.2% | -2.0% | +1.1% | -3.5% | -4.9% |
| EPS (₹) | 18.93 | 9.32 | 9.28 | (3.18) | 24.94 | (5.04) | 25.79 |
| Balance sheet | |||||||
| Total assets | 394 | 257 | 162 | 74.94 | 87.86 | 48.65 | 57.36 |
| Net worth | 144 | 59.27 | 27.95 | (7.25) | 2.19 | (131) | (118) |
| Total debt | 226 | 179 | 116 | 68.27 | 73.60 | 166 | 164 |
| Cash & bank | 7.63 | 12.83 | 5.90 | 3.89 | 25.27 | 11.66 | 16.66 |
| Net working capital | 115 | 36.29 | (22.22) | (107) | (93.46) | (143) | (131) |
| Cash flow | |||||||
| Cash from operations | 31.53 | 26.20 | 4.70 | 19.80 | 40.52 | 16.68 | 44.13 |
| Cash from investing | (56.40) | (51.17) | (16.63) | (8.84) | 0.59 | 8.04 | 63.66 |
| Cash from financing | 22.42 | 25.63 | 13.87 | (31.99) | (28.58) | (17.39) | (108) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 166 | 165 | 162 | 160 | 163 | 172 | 133 | 161 |
| Revenue growth (YoY) | +1.5% | -4.3% | +21.7% | -0.7% | +24.5% | - | - | - |
| Other income | 0.36 | 0.21 | 0.18 | 0.20 | 0.35 | 1.84 | 0.84 | 1.63 |
| Total expenses | 149 | 138 | 136 | 134 | 139 | 142 | 120 | 141 |
| EBITDA | 16.23 | 26.24 | 26.69 | 25.78 | 24.44 | 29.63 | 13.94 | 20.01 |
| EBITDA margin | +9.8% | +15.9% | +16.4% | +16.1% | +15.0% | +17.2% | +10.4% | +12.4% |
| Depreciation | 4.04 | 3.23 | 3.74 | 3.70 | 3.64 | 3.37 | 3.32 | 3.32 |
| Interest | 7.97 | 8.06 | 7.26 | 7.12 | 7.54 | 9.04 | 10.17 | 10.15 |
| Profit before tax | 4.58 | 15.16 | 15.87 | 15.16 | 13.61 | 19.06 | 1.29 | 8.17 |
| Tax | 1.34 | (6.54) | 0.11 | (0.02) | 0.12 | (1.20) | 0.07 | 0.15 |
Financial Statements
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 163 | 172 | 133 | 161 | 131 | 139 | 146 | 144 |
| Revenue growth (YoY) | +24.5% | +23.4% | -8.3% | +11.6% | -10.4% | - | - | - |
| Other income | 0.35 | 1.84 | 0.84 | 1.63 | 0.94 | 26.48 | 0.69 | 0.76 |
| EBITDA | 24.44 | 29.63 | 13.94 | 20.01 | 10.98 | 18.17 | 21.15 | 17.34 |
| EBITDA margin | +15.0% | +17.2% | +10.4% | +12.4% | +8.4% | +13.0% | +14.5% | +12.0% |
| Depreciation | 3.64 | 3.37 | 3.32 | 3.32 | 3.29 | 3.28 | 3.32 | 3.24 |
| Interest | 7.54 | 9.04 | 10.17 | 10.15 | 7.59 | 7.46 | 8.26 | 7.67 |
| Profit before tax | 13.61 | 19.06 | 1.29 | 8.17 | 1.04 | 33.91 | 10.26 | 7.19 |
| Tax | 0.12 | (1.20) | 0.07 | 0.15 | 0.00 | 0.27 | (0.02) | (0.18) |
| Net profit | 13.49 | 20.26 | 1.22 | 8.02 | 1.04 | 33.64 | 10.28 | 7.37 |
| EPS (₹) | 3.95 | 5.98 | 0.35 | 2.34 | 0.31 | 10.08 | 3.13 | 2.25 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Revenue | 600 | 576 | 500 | 511 | 393 | 367 | 391 |
| Revenue growth | +4.1% | +15.2% | -2.3% | +30.2% | +6.8% | -6.1% | - |
| Other income | 3.49 | 28.55 | 0.91 | 77.88 | 2.40 | 83.78 | 9.33 |
| Total expenses | 523 | 506 | 477 | 476 | 374 | 344 | 376 |
| Employee cost | 104 | 86.92 | 81.00 | 74.81 | 64.15 | 67.48 | 75.89 |
| EBITDA | 76.31 | 70.00 | 22.58 | 35.32 | 18.02 | 23.43 | 15.55 |
| EBITDA margin | +12.7% | +12.2% | +4.5% | +6.9% | +4.6% | +6.4% | +4.0% |
| Depreciation | 13.31 | 13.03 | 12.38 | 11.45 | 9.75 | 9.68 | 9.97 |
| Interest | 36.95 | 29.18 | 21.39 | 20.61 | 23.07 | 32.87 | 39.88 |
| Profit before tax | 29.54 | 56.34 | (10.28) | 81.14 | (12.40) | 64.66 | (24.97) |
| Tax | (0.98) | 0.38 | 0.11 | (0.35) | 0.20 | 0.21 | (0.14) |
| Net profit | 33.36 | 33.23 | (6.79) | 5.76 | (12.24) | (18.05) | (24.49) |
| Net profit margin | +5.6% | +5.8% | -1.4% | +1.1% | -3.1% | -4.9% | -6.3% |
| EPS (₹) | 9.32 | 17.09 | (3.18) | 24.94 | (5.04) | 25.79 | 0.00 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 32.77 | 32.75 | 32.71 | 32.67 | 25.02 | 25.00 | 23.72 |
| Reserves & surplus | 20.50 | (10.80) | (65.52) | (56.09) | (181) | (168) | (233) |
| Shareholders' funds (net worth) | 59.27 | 27.95 | (32.81) | (23.42) | (156) | (143) | (209) |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 175 | 110 | 63.64 | 66.52 | 160 | 163 | 232 |
| Unsecured loans | 3.68 | 6.53 | 31.29 | 33.74 | 32.30 | 27.16 | 27.16 |
| Total debt | 179 | 116 | 94.93 | 100 | 192 | 190 | 260 |
| Total liabilities | 257 | 160 | 76.05 | 88.91 | 49.73 | 58.40 | 61.07 |
| Assets | |||||||
| Gross block | 293 | 248 | 239 | 227 | 216 | 203 | 202 |
| Net block | 201 | 167 | 167 | 167 | 167 | 164 | 172 |
| Capital work in progress | 5.38 | 3.01 | 1.61 | 2.35 | 11.01 | 13.89 | 8.97 |
| Investments | 0.15 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Inventories | 37.68 | 36.02 | 21.99 | 49.73 | 24.85 | 12.26 | 19.33 |
| Sundry debtors | 114 | 89.44 | 68.98 | 62.80 | 34.47 | 50.79 | 44.41 |
| Cash & bank balances | 12.83 | 5.90 | 3.93 | 25.31 | 11.70 | 16.70 | 5.25 |
| Loans & advances | 28.65 | 27.92 | 26.91 | 33.40 | 26.51 | 10.16 | 25.43 |
| Total current assets | 193 | 159 | 122 | 171 | 97.53 | 89.91 | 94.42 |
| Total current liabilities | 157 | 184 | 227 | 264 | 239 | 220 | 225 |
| Net working capital | 36.42 | (24.27) | (106) | (92.40) | (142) | (130) | (131) |
| Total assets | 257 | 160 | 76.05 | 88.91 | 49.73 | 58.40 | 61.07 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.40 | 1.49 | 22.53 | 10.00 | 2.66 | 2.74 | 2.87 |
| Net cash from operating activities | 26.10 | 3.98 | 19.80 | 40.52 | 16.68 | 44.13 | 29.73 |
| Net cash from investing activities | (51.17) | (16.63) | (8.84) | 0.59 | 8.04 | 63.66 | (3.07) |
| Net cash from financing activities | 25.73 | 14.55 | (31.99) | (28.58) | (17.39) | (108) | (26.78) |
| Net change in cash | 0.66 | 1.91 | (21.03) | 12.52 | 7.34 | (0.08) | (0.13) |
| Closing cash | 12.83 | 5.90 | 3.93 | 25.31 | 11.70 | 16.70 | 5.25 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +4.1% | +15.2% | -2.3% | +30.2% | +6.8% | -6.1% | - |
| EBITDA growth | +9.0% | +210.0% | -36.1% | +96.0% | -23.1% | +50.7% | - |
| PBT growth | -47.6% | +9998.0% | - | +9998.0% | - | +9998.0% | +22.9% |
| Net income growth | +0.4% | +589.4% | -217.9% | +147.1% | +32.2% | +26.3% | - |
| Revenue CAGR (3Y) | +5.5% | +13.6% | +10.8% | +9.3% | +1.9% | -5.4% | -2.6% |
| EBITDA CAGR (3Y) | +29.3% | +57.2% | -1.2% | +31.5% | - | +8.2% | -21.7% |
| Profitability & leverage | |||||||
| Net income margin | +5.1% | +9.7% | -2.1% | +15.9% | -3.2% | +17.5% | -6.3% |
| Return on capital employed | +21.0% | +33.5% | 0.0% | +16.1% | 0.0% | +8.0% | 0.0% |
| Return on net worth | +20.0% | +49.8% | 0.0% | +306.0% | 0.0% | +36.2% | 0.0% |
| Debt / equity | 3.38 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 2.83 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 58.65 | 51.22 | 209.71 | 86.34 | 278.96 | 239.05 | 714.70 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.22 | 2.36 | 2.15 | 2.31 | 1.87 | 1.81 | 1.95 |
| Inventory turnover | 16.27 | 19.85 | 13.93 | 13.71 | 21.15 | 23.26 | 24.16 |
| Debtors turnover | 5.91 | 7.27 | 7.58 | 10.51 | 9.21 | 7.72 | 10.60 |
| EPS (₹) | 9.32 | 17.09 | (3.18) | 24.94 | (5.04) | 25.79 | 0.00 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 16.26 | 6.70 | (10.07) | (7.27) | (62.46) | (57.39) | (88.23) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 166 | 165 | 162 | 160 | 163 | 172 | 133 | 161 |
| Revenue growth (YoY) | +1.5% | -4.3% | +21.7% | -0.7% | +24.5% | - | - | - |
| Other income | 0.36 | 0.21 | 0.18 | 0.20 | 0.35 | 1.84 | 0.84 | 1.63 |
| Total expenses | 149 | 138 | 136 | 134 | 139 | 142 | 120 | 141 |
| EBITDA | 16.23 | 26.24 | 26.69 | 25.78 | 24.44 | 29.63 | 13.94 | 20.01 |
| EBITDA margin | +9.8% | +15.9% | +16.4% | +16.1% | +15.0% | +17.2% | +10.4% | +12.4% |
| Depreciation | 4.04 | 3.23 | 3.74 | 3.70 | 3.64 | 3.37 | 3.32 | 3.32 |
| Interest | 7.97 | 8.06 | 7.26 | 7.12 | 7.54 | 9.04 | 10.17 | 10.15 |
| Profit before tax | 4.58 | 15.16 | 15.87 | 15.16 | 13.61 | 19.06 | 1.29 | 8.17 |
| Tax | 1.34 | (6.54) | 0.11 | (0.02) | 0.12 | (1.20) | 0.07 | 0.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 650 | 600 | 578 | 500 | 511 | 393 | 367 |
| Revenue growth | +8.5% | +3.8% | +15.6% | -2.3% | +30.2% | +6.8% | - |
| Other income | 0.94 | 3.49 | 0.90 | 0.91 | 77.88 | 2.40 | 83.78 |
| Total expenses | 547 | 523 | 506 | 477 | 476 | 374 | 344 |
| Employee cost | 120 | 102 | 86.92 | 81.00 | 74.81 | 64.15 | 67.48 |
| EBITDA | 103 | 76.41 | 72.10 | 22.58 | 35.33 | 18.02 | 23.43 |
| EBITDA margin | +15.9% | +12.8% | +12.5% | +4.5% | +6.9% | +4.6% | +6.4% |
| Depreciation | 14.31 | 13.41 | 13.03 | 12.38 | 11.45 | 9.75 | 9.68 |
| Interest | 29.98 | 36.95 | 29.18 | 21.39 | 20.61 | 23.07 | 32.87 |
| Profit before tax | 59.80 | 29.54 | 30.79 | (10.28) | 81.15 | (12.40) | 64.66 |
| Tax | (6.33) | (0.98) | 0.38 | 0.11 | (0.35) | 0.20 | 0.21 |
| Net profit | 69.66 | 28.47 | 29.92 | (10.08) | 5.44 | (13.81) | (18.17) |
| Net profit margin | +10.7% | +4.8% | +5.2% | -2.0% | +1.1% | -3.5% | -4.9% |
| EPS (₹) | 18.93 | 9.32 | 9.28 | (3.18) | 24.94 | (5.04) | 25.79 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 34.94 | 32.77 | 32.75 | 32.71 | 32.67 | 25.02 | 25.00 |
| Reserves & surplus | 110 | 20.50 | (10.80) | (39.96) | (30.48) | (156) | (143) |
| Shareholders' funds (net worth) | 144 | 59.27 | 27.95 | (7.25) | 2.19 | (131) | (118) |
| Secured loans | 217 | 175 | 109 | 63.64 | 66.72 | 160 | 163 |
| Unsecured loans | 8.91 | 3.68 | 6.53 | 4.63 | 6.88 | 5.64 | 0.50 |
| Total debt | 226 | 179 | 116 | 68.27 | 73.60 | 166 | 164 |
| Total liabilities | 394 | 257 | 162 | 74.94 | 87.86 | 48.65 | 57.36 |
| Assets | |||||||
| Gross block | 335 | 293 | 248 | 239 | 227 | 216 | 203 |
| Net block | 229 | 201 | 167 | 167 | 167 | 167 | 164 |
| Capital work in progress | 25.42 | 5.38 | 3.01 | 1.61 | 2.35 | 11.01 | 13.89 |
| Investments | 0.03 | 0.15 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 |
| Inventories | 50.63 | 37.68 | 36.02 | 21.99 | 49.73 | 24.85 | 12.26 |
| Sundry debtors | 143 | 114 | 88.76 | 68.98 | 62.80 | 34.47 | 50.79 |
| Cash & bank balances | 7.63 | 12.83 | 5.90 | 3.89 | 25.27 | 11.66 | 16.66 |
| Loans & advances | 37.02 | 28.52 | 27.92 | 25.33 | 31.89 | 24.97 | 8.67 |
| Total current assets | 239 | 193 | 159 | 120 | 170 | 95.95 | 88.38 |
| Total current liabilities | 124 | 157 | 181 | 227 | 263 | 239 | 220 |
| Net working capital | 115 | 36.29 | (22.22) | (107) | (93.46) | (143) | (131) |
| Total assets | 394 | 257 | 162 | 74.94 | 87.86 | 48.65 | 57.36 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 4.06 | 3.40 | 1.46 | 22.49 | 9.96 | 2.62 | 2.71 |
| Net cash from operating activities | 31.53 | 26.20 | 4.70 | 19.80 | 40.52 | 16.68 | 44.13 |
| Net cash from investing activities | (56.40) | (51.17) | (16.63) | (8.84) | 0.59 | 8.04 | 63.66 |
| Net cash from financing activities | 22.42 | 25.63 | 13.87 | (31.99) | (28.58) | (17.39) | (108) |
| Net change in cash | (2.45) | 0.66 | 1.94 | (21.03) | 12.53 | 7.34 | (0.09) |
| Closing cash | 7.63 | 12.83 | 5.90 | 3.89 | 25.27 | 11.66 | 16.66 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +8.5% | +3.8% | +15.6% | -2.3% | +30.2% | +6.8% | - |
| EBITDA growth | +35.0% | +6.0% | +219.3% | -36.1% | +96.1% | -23.1% | - |
| PBT growth | +102.4% | -4.1% | +9998.0% | - | +9998.0% | - | +9998.0% |
| Net income growth | +144.7% | -4.9% | +396.8% | -285.3% | +139.4% | +24.0% | - |
| Revenue CAGR (3Y) | +9.2% | +5.5% | +13.8% | +10.8% | +9.3% | +1.9% | -5.6% |
| EBITDA CAGR (3Y) | +65.9% | +29.3% | +58.8% | -1.2% | +31.5% | - | +7.5% |
| Profitability & leverage | |||||||
| Net income margin | +10.2% | +5.1% | +5.3% | -2.1% | +15.9% | -3.2% | +17.5% |
| Return on capital employed | +22.4% | +20.0% | +31.9% | 0.0% | +17.5% | 0.0% | +8.5% |
| Return on net worth | +37.3% | +18.3% | +38.3% | 0.0% | +37.0% | 0.0% | +49.0% |
| Debt / equity | 1.99 | 3.38 | 8.94 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 1.52 | 2.83 | 4.29 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 33.75 | 58.65 | 49.40 | 209.71 | 86.31 | 278.96 | 239.05 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.07 | 2.21 | 2.37 | 2.15 | 2.31 | 1.87 | 1.81 |
| Inventory turnover | 14.73 | 16.27 | 19.92 | 13.93 | 13.71 | 21.15 | 23.26 |
| Debtors turnover | 5.05 | 5.91 | 7.33 | 7.58 | 10.51 | 9.21 | 7.72 |
| EPS (₹) | 18.93 | 9.32 | 9.28 | (3.18) | 24.94 | (5.04) | 25.79 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 41.34 | 16.26 | 6.70 | (2.26) | 0.57 | (52.23) | (47.14) |
To see the full year-wise statements and ratios of Wanbury Limited, buy the company report.
Board of directors of Wanbury Limited
Wanbury has 6 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Anupama Vaidya | Director | 17 Mar 2022 | 4 Years 7 Months | Current |
| Chandran Krishnamoorthy Also directs: Wanbury Skin Health Limited | Whole-Time Director | 01 Sep 2010 | 16 Years 1 Months | Current |
| Manojkumar Khubchand Gursahani Also directs: Aison Technology LLP, Katha Story Labs Private Limited | Director | 08 Jan 2025 | 1 Years 9 Months | Current |
| Pallavur Sankar Dass Vaidyanathan Also directs: Wanbury Skin Health Limited, Futura Surgicare Private Limited, Suturemate Technologies Private Limited and 1 more | Director | 08 Jan 2025 | 1 Years 9 Months | Current |
| Mridul Sumanlal Mehta Also directs: Valueadd Advisors Private Limited | Director | 12 Aug 2024 | 2 Years 2 Months | Current |
| Mohan Kumar Rayana | Whole-Time Director | 21 Aug 2023 | 3 Years 2 Months | Current |
Peer comparison
Wanbury Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Wanbury Limitedthis company | ₹650.27 Cr (FY 2026) | ₹69.66 Cr | 10.7% | 8.5% | 742 | Navi Mumbai, Maharashtra, India |
| Samarth Life Sciences Private Limited | ₹624.79 Cr (FY 2025) | 11.0% | Mumbai, Maharashtra, India | |||
| Ra Chem Pharma Limited | ₹621.32 Cr (FY 2021) | 15.0% | Hyderabad, Telangana, India | |||
| Inventia Healthcare Limited | ₹620.73 Cr (FY 2025) | -19.0% | Mumbai, Maharashtra, India | |||
| Sri Krishna Pharmaceuticals Limited | ₹608.24 Cr (FY 2025) | -13.0% | Telangana, India | |||
| Malik Lifesciences Private Limited | ₹595.52 Cr (FY 2025) | 11.0% | Delhi, India | |||
| Global Calcium Private Limited | ₹594.12 Cr (FY 2025) | 2.0% | Hosur, Tamil Nadu, India | |||
| Acme Formulation Private Limited | ₹577 Cr (FY 2025) | -2.0% | Himachal Pradesh, India |
To see the full peer comparison of Wanbury Limited, buy the company report.
Auditor
Wanbury Limited is audited by V. Parekh and Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| V. Parekh and Associates | FY 2023 | 107488W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 43.00%, foreign institutional investors hold 0.90%, domestic institutional investors hold 0.10% and retail and other public shareholders hold 56.00%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 43.00% | 43.00% | 43.10% | 39.60% |
| Public | 57.00% | 57.00% | 56.90% | 60.40% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 24 Jun 2026 | 101323851 | Sbicap Trustee Company Limited | ₹205 Cr | Open | |
| 23 Feb 2024 | 100877119 | Sbicap Trustee Company Limited | ₹65 Cr | Open | |
| 22 Apr 2014 | 10490144 | Others | ₹6 Cr | Open | |
| 27 Feb 2025 | 101084774 | Others | ₹200 Cr | Satisfied | |
| 10 Jun 2024 | 100940313 | Sbicap Trustee Company Limited | ₹60 Cr | Satisfied |
To see the full charge records of Wanbury Limited, buy the company report.
Total charge records: 32 View all charges
Deals & funding
Wanbury Limited has 57 deals on record (53 market trades, 1 debt financing, 1 secondary share transfer), with disclosed funding of ₹147.23 Cr; the latest was in July 2026.
Deals on record (5 of 57)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2026 | Market trade | ₹28.96 Cr | Buyer: Junomoneta Finsol Private Limited , NK Securities Research Private Limited , Silverleaf Capital Services Private Limited Seller: Junomoneta Finsol Private Limited , NK Securities Research Private Limited , GRT Strategic Ventures LLP |
| Sep 2025 | Market trade | ₹4.73 Cr | Seller: Magnum Equifin Private Limited |
| Mar 2025 | Market trade | ₹10.89 Cr | Buyer: Resonance Opportunities Fund Seller: Surbhi Investments and Trading Company Private Limited |
| May 2024 | Market trade | ₹8.87 Cr | Buyer: Surbhi Investments and Trading Company Private Limited Seller: an individual |
| Oct 2023 | Market trade | ₹1.8 Cr | Seller: Multiplier Share and Stock Advisors Private Limited |
To see the full deal history of Wanbury Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Wanbury Limited has 154 court cases on record: 88 filed by Wanbury, 67 filed against it. 19 cases are pending and 135 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 107 | 36 | 16 |
| District courts | 38 | 26 | 3 |
| Supreme Court | 8 | 4 | 0 |
| NCLT | 1 | 1 | 0 |
Cases on record (5 of 154)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, GUJARAT | Court case (RA) | Filed by the company against Intas Pharmaceuticals Limited and 1 other | Pending |
| District court, Bharuch, Gujarat | Court case (SMST S) | Filed against the company by Element Chemilink Pvt. Ltd | Disposed |
| NCLT, Mumbai | Insolvency matter | Filed against the company by Edelweiss Asset Reconstruction Company Limited | Disposed |
| High Court, TAMIL NADU | Court case (COMP.A) | Filed by the company against Bafna Pharmaceuticals Limited | Disposed |
| High Court, CHANDIGARH (UT) | Company petition | Filed by the company against M/S Panacea Biotec Ltd | Disposed |
To see the full case history of Wanbury Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Wanbury Limited has 12 MSME Form 1 returns on record between 2019 and 2024, listing 205 overdue payments to 27 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 27)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Iris Regtech Solutions Limited | |||
| Aarham Chemical | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Wanbury Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Wanbury Limited has a workforce of 742 employees on its EPFO records as of Apr 05, 2024, across 2 active EPFO establishments.
GST
Wanbury has 10 GST registrations: 10 active. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AABCP5939P1ZP | Maharashtra | Active | 01 Jul 2017 |
| 04AABCP5939P1ZX | Chandigarh | Active | 01 Jul 2017 |
| 05AABCP5939P1ZV | Uttarakhand | Active | 01 Jul 2017 |
| 07AABCP5939P1ZR | Delhi | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Wanbury Limited, buy the company report.
Recent activity
Wanbury Limited has 44 board changes on record since 2005: 26 appointments and 18 cessations. The latest: Manojkumar Khubchand Gursahani was appointed as Director on 08 Jan 2025.
126 earlier events are in the company report.
News
Frequently asked questions
Wanbury is an active public limited company based in Navi Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 11 August 1988 (38+ years old) and is registered under CIN L51900MH1988PLC048455. Listed on BSE: 524212 and NSE: WANBURY.
Wanbury reported revenue of ₹650.27 Cr for FY 2025-26 (up 8.5% YoY) based on standalone financials.
Wanbury has 6 current directors:
- Chandran Krishnamoorthy - Whole-Time Director
- Mohan Kumar Rayana - Whole-Time Director
- Anupama Vaidya - Director
- Manojkumar Khubchand Gursahani - Director
- Pallavur Sankar Dass Vaidyanathan - Director
- Mridul Sumanlal Mehta - Director
The latest financial statements of Wanbury on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 18 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Wanbury is 27AABCP5939P1ZP, registered in Maharashtra. The company has 10 GST registrations in all, of which 10 are active. Other active GSTINs include 04AABCP5939P1ZX (Chandigarh), 05AABCP5939P1ZV (Uttarakhand), 07AABCP5939P1ZR (Delhi).
The CIN (Corporate Identification Number) of Wanbury is L51900MH1988PLC048455. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Wanbury is a listed company as per MCA records. Its shares are listed on both BSE (code: 524212) and NSE (symbol: WANBURY).
Wanbury has 154 court cases on record: 88 filed by the company and 67 filed against it. 19 are pending. Most are in the high courts.
Wanbury was incorporated on 11 August 1988, making it 38+ years old. It is registered with the Registrar of Companies, Mumbai.
Wanbury has 57 deals on record (53 market trades, 1 debt financing, 1 secondary share transfer), with disclosed funding of ₹147.23 Cr; the latest was in July 2026.
The peers of Wanbury by revenue are Samarth Life Sciences Private Limited, Ra Chem Pharma Limited, Inventia Healthcare Limited, Sri Krishna Pharmaceuticals Limited, Malik Lifesciences Private Limited and 2 more, all in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Manojkumar Khubchand Gursahani was appointed as Director on 08 Jan 2025. Pallavur Sankar Dass Vaidyanathan was appointed as Director on 08 Jan 2025. Pravin Dilip Pawar ceased to be Director on 17 Nov 2024. Wanbury has 44 board changes on record in total.